[1] Zhao YY, Liu HX, Meng XJ, et al. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. N Engl J Med. 2026. doi:10.1056/NEJMoa2610229.(TAISHAN-302)
[2] U.S. Food and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer (15 Dec 2023). 。
[3] Vulsteke C, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026;394:1257–1269. doi:10.1056/NEJMoa2511674.(KEYNOTE-905/EV-303)
[4] U.S. Food and Drug Administration. FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer. 10 Jul 2026.(KEYNOTE-B15/EV-304)
[5] Sheng X, et al. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med. 2025;393:2324–2337. doi:10.1056/NEJMoa2511648.
[6] Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269-274. doi:10.1038/85339.
[7] Steinberger P, Majdic O, Derdak SV, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 2004;172(4):2352-2359. doi:10.4049/jimmunol.172.4.2352.
[8] Leitner J, Klauser C, Pickl WF, et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39(7):1754-1764. PMID:19544488.
[9] Wu S, Hu C, Hui K, Jiang X. Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature. Front Oncol. 2024;14:1408051. doi:10.3389/fonc.2024.1408051.
[10] Seaman S, Zhu Z, Saha S, et al. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell. 2017;31(4):501-515.e8. doi:10.1016/j.ccell.2017.03.005.
[11] Sun H, Gao F, Liu Y, Shao J. Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis. BMC Urol. 2024;24(1):57. doi:10.1186/s12894-024-01446-3.
[12] MediLink Therapeutics. NDA Acceptance for Tam-Peli (YL201) in recurrent small-cell lung cancer by China NMPA. 2 Sep 2026; TAISHAN-302/NCT06612151.
[13] MediLink Therapeutics. Tam-Peli (YL201) Phase III TAISHAN-301 in recurrent/metastatic nasopharyngeal carcinoma and China NDA acceptance; MediLink-Roche global licensing update. 2026.
[14] ClinicalTrials.gov. NCT07487896 (TAISHAN-303, ESCC);NCT07803783 (TAISHAN-305, PDAC). Tambotatug pelitecan Phase III studies.
[15] Hansoh Pharma / GSK. ARTEMIS-008 Phase III study of risvutatug rezetecan (HS-20093/GSK5764227) in relapsed SCLC: OS primary endpoint met; China BLA accepted in Sep 2026.
[16] Hansoh Pharma / GSK. ARTEMIS-011 Phase III osteosarcoma study: IRC-assessed PFS primary endpoint met;ClinicalTrials.gov NCT07464327, Phase III risvutatug rezetecan plus adebrelimab in previously treated non-squamous NSCLC.
[17] Daiichi Sankyo / Merck. Ifinatamab deruxtecan (I-DXd) BLA granted FDA Priority Review for previously treated ES-SCLC; PDUFA date 10 Oct 2026;IDeate-Lung02 (NCT06203210);IDeate-PanTumor02 (NCT06330064).
[18] BioNTech / DualityBio. Elfetabart drozuntecan (BNT324/DB-1311) development update;Phase III mCRPC study NCT07365995;Phase 1/2 NCT05914116 and Phase II combination study NCT06953089.
[19] ClinicalTrials.gov / ASCO. QLC5508 (MHB088C): NCT06954246 (Phase III relapsed SCLC), NCT07463573 (Phase III ESCC), NCT07102004 (mCRPC Phase I/II), NCT06951243 (extrapulmonary neuroendocrine cancer Phase II).
[20] B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies. 2026 review summarizing clinical-stage B7-H3 modalities, including IBI129, ILB-3101 and non-ADC platforms.
[21] Zhang X, et al. An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors. J Clin Oncol. 2026;44(suppl):3011. doi:10.1200/JCO.2026.44.16_suppl.3011;NCT06736327;NCT07296809.
[22] Mabwell. 7MW3711 B7-H3 ADC clinical development updates: Phase I/II advanced solid tumors, lung cancer and immunotherapy combination programs; FDA orphan drug designation for SCLC. 2025-2026.
[23] MacroGenics. MGC026 Phase I study NCT06242470 and clinical update, 23 Jul 2026; tumor-specific expansion cohorts include SCCHN, endometrial cancer, melanoma and soft tissue sarcoma.
[24] InnoCare Pharma. ICP-B794 B7-H3 ADC preclinical data at AACR 2026 and Phase I dose-escalation clinical development update. 2026.
[25] IDEAYA Biosciences. IDE034, a B7-H3/PTK7 bispecific TOP1 ADC: first patient dosed in Phase I on 25 Feb 2026; current solid-tumor development plan.
[26] ClinicalTrials.gov. NCT05405621. A Phase I study of BAT8009 in patients with locally advanced/metastatic solid tumors.
[27] Shenderov E, et al. Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer. 2026.
[28] BeOne Medicines Ltd. Annual Report 2025. BGB-C354, an anti-B7-H3 ADC: development discontinued.
[29] T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008. 。
[30] Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. 。
[31] Aicher WK, et al. Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. 2021;
[32] Klümper N, et al. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res. 2023.
[33] 本期汇总的EV耐药机制研究与病例观察:包括Nectin-4保留及MDR1/MRP1/BCRP等药物外排相关研究和病例。
[34] Yamato M, et al. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Mol Cancer Ther. 2022;21:635–646.
[35] Rudin CM, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. 2026;44:261–273.
[36] ClinicalTrials.gov. NCT06330064. IDeate-PanTumor02. B7-H3–directed I-DXd study including an urothelial carcinoma cohort
[37] ClinicalTrials.gov. NCT04879329. A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2.(RC48-G001)